| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Common Stock | Options Exercise | $701,845 | +22,416 | +259% | $31.31 | 31,063 | 27 Feb 2025 | Direct | F1 |
| transaction | PFE | Common Stock | Tax liability | $14,433 | -553 | -1.8% | $26.10 | 30,510 | 27 Feb 2025 | Direct | F2 |
| transaction | PFE | Common Stock | Tax liability | $547,104 | -20,994 | -69% | $26.06 | 9,516 | 27 Feb 2025 | Direct | F3, F4 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Stock Appreciation Rights | Options Exercise | $0 | -22,416 | -100% | $0.000000 | 0 | 27 Feb 2025 | Common Stock | 22,416 | $31.31 | Direct |
| Id | Content |
|---|---|
| F1 | The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
| F2 | The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
| F3 | The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). |
| F4 | Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |